Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Atrium Therapeutics (Nasdaq: RNA) granted equity awards under its 2026 Employment Inducement Incentive Award Plan to eight newly hired non-executive employees on June 20, 2026.

Rhea-AI Summary

Atrium Therapeutics (Nasdaq: RNA) granted equity awards under its 2026 Employment Inducement Incentive Award Plan to eight newly hired non-executive employees on June 20, 2026.

The employees received options for 66,000 shares at $12.66 per share and 33,000 RSUs, with multi-year time-based vesting schedules, approved under Nasdaq Listing Rule 5635(c)(4).

Positive

• Equity awards cover 66,000 stock options at a $12.66 exercise price
• Additional 33,000 restricted stock units granted to eight new employees
• Multi-year vesting schedules support employee retention and long-term alignment

Negative

• Awards represent potential issuance of up to 99,000 additional common shares
• Grants made outside existing stockholder-approved equity incentive plans

Argus Jun 24 session

+0.16% close to close Open Argus

Details

News Market Reaction – RNA

On Jun 24, the first trading day after this news, RNA closed 0.16% above the previous close.

Data tracked by StockTitan Argus for the Jun 24 session.

Key Figures

Inducement option grants: 66,000 options Inducement RSU grants: 33,000 RSUs Option exercise price: $12.66 per share +5 more

Inducement option grants

66,000 options

Aggregate non-qualified stock options to eight new non-executive hires

Inducement RSU grants

33,000 RSUs

Aggregate restricted stock units to eight new non-executive hires

Option exercise price

$12.66 per share

Exercise price for inducement stock options, based on prior Nasdaq close

Common stock par value

$0.001 per share

Par value of Atrium Therapeutics common stock referenced in awards

Initial vesting cliff

25% after 1 year

Cliff vesting for both options and RSUs under inducement awards

Option vesting schedule

36 monthly installments

Remaining 75% of options vest monthly after first anniversary

RSU vesting schedule

3 annual installments

Remaining 75% of RSUs vest in three yearly installments after year one

New hires

8 employees

Non-executive individuals receiving inducement equity awards

Historical Context

5 past events · Latest: May 14

5 events

1. May 14

   Q1 earnings

   24h Move

   -0.3%

   First standalone quarterly financials and pipeline update after spin-off.

2. Apr 23

   Milestone payment

   24h Move

   +1.4%

   Bristol Myers Squibb development milestone under global cardiovascular collaboration.

3. Apr 20

   Inducement grants

   24h Move

   -5.4%

   Equity inducement awards to new hires under 2026 Inducement Plan.

4. Feb 27

   Company launch

   24h Move

   -79.7%

   Public launch with substantial cash to advance RNA cardiomyopathy programs.

5. Feb 26

   Conference data

   24h Move

   -79.7%

   Multiple MDA conference presentations including long-term clinical data updates.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

non-qualified stock options, restricted stock units, nasdaq listing rule 5635(c)(4), exercise price, +1 more

5 terms

non-qualified stock options financial

"The employees received, in the aggregate, non-qualified stock options to purchase 66,000 shares"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"and restricted stock units for an aggregate of 33,000 shares of the Company's common stock"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"as a material inducement to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"with an exercise price of $12.66 per share, the closing price of the Company's common stock"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"25% of which will vest and become exercisable on the first anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, June 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on June 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of eight non-executive individuals newly hired by the Company.

The employees received, in the aggregate, non-qualified stock options to purchase 66,000 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $12.66 per share, the closing price of the Company's common stock as reported by Nasdaq on the last date of trading preceding the effective date of the grant, 25% of which will vest and become exercisable on the first anniversary of the grant date, and the remaining underlying shares will vest in 36 substantially equal installments each month thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 33,000 shares of the Company's common stock, 25% of which will vest in the first anniversary of the grant date, and the remaining underlying shares will vest in three substantially equal installments each year thereafter, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the "Awards."

All of the above-described Awards were granted outside of the Company's stockholder-approved equity incentive plans pursuant to the 2026 Inducement Plan, which was adopted by the Company's board of directors (the "Board") in April 2026. The Awards were approved by the Board's Human Capital Management Committee, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides. Atrium Therapeutics' platform is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from demonstrated delivery to the skeletal muscle and applies it for efficient delivery to the heart with the potential to overcome challenges associated with non-specific tissue delivery. The Company's pipeline consists of two precision cardiology candidates, ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome and ATR 1086 for PLN (phospholamban) cardiomyopathy, and two undisclosed research targets in rare cardiomyopathies.

For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/ and engage with us on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/atrium-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302808194.html

SOURCE Atrium Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement grants did Atrium Therapeutics (RNA) announce on June 23, 2026?

Atrium Therapeutics announced stock option and RSU inducement grants for eight new employees. According to Atrium Therapeutics, the awards include options for 66,000 shares and 33,000 restricted stock units, granted under the 2026 Employment Inducement Incentive Award Plan.

How many Atrium Therapeutics (RNA) shares are covered by the new inducement awards?

The inducement awards cover 99,000 Atrium Therapeutics common shares in total. According to Atrium Therapeutics, employees received 66,000 non-qualified stock options and 33,000 restricted stock units as a material inducement to their employment with the company.

What is the exercise price and vesting schedule for Atrium Therapeutics (RNA) inducement stock options?

The inducement stock options have a $12.66 exercise price per share. According to Atrium Therapeutics, 25% vest on the first anniversary of the June 20, 2026 grant date, with the remaining shares vesting in 36 substantially equal monthly installments, subject to continued service.

How do Atrium Therapeutics (RNA) inducement RSUs vest over time?

The inducement RSUs vest over four years with time-based milestones. According to Atrium Therapeutics, 25% vest on the first anniversary of the grant date, and the remaining shares vest in three substantially equal annual installments, subject to continued employment.

Were Atrium Therapeutics (RNA) inducement awards granted under stockholder-approved plans?

The inducement awards were granted outside existing stockholder-approved equity plans. According to Atrium Therapeutics, they were issued under the 2026 Employment Inducement Incentive Award Plan, adopted by the board in April 2026, consistent with Nasdaq Listing Rule 5635(c)(4).

Who approved the Atrium Therapeutics (RNA) inducement grants under Nasdaq Listing Rule 5635(c)(4)?

The grants were approved by the board’s Human Capital Management Committee. According to Atrium Therapeutics, this committee is composed solely of independent directors and authorized the awards as a material inducement for eight new non-executive employees to join the company.

What could the Atrium Therapeutics (RNA) inducement grants mean for existing shareholders?

The inducement grants could modestly increase Atrium’s share count over time. According to Atrium Therapeutics, the awards cover 66,000 options and 33,000 RSUs, which may convert into common shares as they vest and options are exercised.